Alessandro Prestipino, Alica Emhardt, Konrad Aumann, Gorantla SP, Sandra Duquesne,Sandra Pennisi, Petya Apostolova, Pia Veratti, Hauke Busch, Melanie Börries, Michael Hettich, Gabriele Niedermann, Khalid Shoumariyeh, Christine Dierks, Heiko Becker, Wolfgang Melchinger, Annette Schmitt-Gräff , Reinhold Schirmbeck , Marie Follo, Dietmar Pfeifer, Frederike Hartl, Susana Minguet, Bruce R Blazar, Justus Duyster, Cornelius Miething, Heike Pahl, Nikolas von Bubnoff, Robert Zeiser(2018) Oncogenic JAK2 activation causes PD-L1 expression via STAT3-phosphorylation mediating immune escape in myeloprolifeartive neoplasms, Science Translational Medicine , Doi:10.1126\scitranslmed.aam7729.,
-.
Gorantla SP, Zirlik K, Reiter A, Yu C, Illert AL, Von Bubnoff N, Duyster J(2015) F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP- and SRC: a novel mode of kinase inhibitor resistance, Leukemia , 10.1038/leu.2015.70.,
-.
Gorantla SP*, N von Bubnoff*, R A Engh, T M Oliveira, S Thöne, E Aberg, C P eschel, Duyster J(2011) The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro, Oncogene , 24,
30(8):933-43.
Gorantla SP, Dechow TN, Grundler R, Illert AL, Zum Büschenfelde CM, Kremer M, Peschel C, Duyster J.(2010) Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice, Blood , 116(22),
4600-11.
Gorantla SP*, N von Bubnoff*, S Thöne, C Peschel, J Duyster(2006) The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107, Blood , 15,
107(12)-4970-1 .
Gorantla SP *, N von Bubnoff*, R K Kancha, Lordick F, C Peschel, Duyster J(2005) The systemic mastocytosis- specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107, Leukemia , 19,
1670-1671.